---
title: New systemic treatment paradigms in resectable non-small cell lung cancer and
  variations in patient access across Europe
date: '2024-03-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38476748/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240313180711&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The treatment landscape of resectable early-stage non-small cell lung
  cancer (NSCLC) is set to change significantly due to encouraging results from randomized
  trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted
  therapy. As of January 2024, marketing authorization has been granted for four new
  indications in Europe, and regulatory approvals for other study regimens are expected.
  Because cost-effectiveness and reimbursement criteria for novel treatments ...
disable_comments: true
---
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments ...